The US Food and Drug Administration (FDA) has authorized the marketing of Zyn nicotine pouches, citing extensive scientific review. The move marks the first time the agency has approved a nicotine pouch product.
Zyn garnered attention online after promotional efforts by influencers, who touted its benefits as “lower risk” compared to cigarettes and most smokeless tobacco products. The FDA stated that its benefits outweigh risks, including youth use, which remains low.
However, the agency is closely monitoring the market to prevent youth use and protect public health. The director of the FDA’s Center for Tobacco Products emphasized the need for responsible marketing practices.
The surge in Zyn pouch sales has led to a new factory plan by Philip Morris International, valued at $600 million. This development echoes the teen vaping boom in the late 2010s, with social media chatter around Zyn similar to that seen during the previous crisis.
Source: https://www.axios.com/2025/01/16/zyn-marketing-fda-authorized-nicotine-pouch